Market Overview:
The global immunosuppressant for systemic lupus erythematosus market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of autoimmune diseases, rising awareness about available treatment options, and growing demand for better-quality life. Immunosuppressants are used as a part of the treatment regimen for patients with autoimmune diseases such as systemic lupus erythematosus (SLE). These drugs help in suppressing the immune system and preventing it from attacking healthy cells and tissues. Based on type, the global immunosuppressant for SLE market is segmented into cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporine A, tacrolimus, methotrexate leflunomide,, vincristine,, and other immunosuppressants. Cyclophosphamide is currently one of the most commonly used drugs in this category owing to its high efficacy in treating autoimmune diseases such as SLE. It also has a low incidence of adverse effects compared with other drugs in its class.
Product Definition:
An immunosuppressant is a drug that suppresses the immune system. Immunosuppressants are used to treat autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and psoriasis. Immunosuppressants can also be used to prevent rejection of transplanted organs.
Cyclophosphamide:
Lupus Erythematosus or lupus is a chronic autoimmune disorder of the skin, joints, and/or kidneys. It commonly affects women more than men. The disease may develop after 10 to 50 years of age and there is no known cure at present. However, treatment for the condition involves drugs that reduce inflammation by inhibiting cytokines (immune proteins) such as cyclophosphamide (Cytoxan).
Mycophenolate Mofetil:
Mycophenolate mofetil is a myco-antibody inhibitor. It works by decreasing the ability of myco-antibodies to interact with their target cells. The drug was approved by the U.S Food and Drug Administration (FDA) in 1997 as an immunosuppressant for lupus erythematosus, an autoimmune disease affecting connective tissues such as cartilage, joints, and blood vessels.
Application Insights:
On the basis of application, the global immunosuppressant for systemic lupus erythematosus market is segmented into hospital, clinic and pharmacy. Hospital was estimated as the largest segment in 2017 owing to a high prevalence of patients suffering from SLE across various hospitals in developed countries. Moreover, an increase in healthcare spending along with rising awareness about preventive measures taken against diseases such as cancer will boost market growth over the forecast period.
Clinic and pharmacy are expected to be fastest growing segments during the forecast period due to increasing awareness among individuals suffering from Systemic Lupus Erythematosus (SLE) regarding available treatment options along with advancements made by pharmaceutical companies for developing new drugs specific towards this condition which helps control its symptoms & complications at lower costs than other drugs do. For instance, according to data published by Arthritis Foundation Inc.
Regional Analysis:
North America dominated the global immunosuppressant market in 2017. The presence of a large number of autoimmune diseases treatment centers and high adoption rate for newer generation immunosuppressants are some factors attributing to its largest share. In addition, increasing R&D expenditure by pharmaceutical companies is also one factor that can be attributed to its largest share.
Asia Pacific is expected to grow at the fastest CAGR during the forecast period due to rising awareness about available treatments and growing disposable income resulting in an increase in healthcare expenditure & demand for effective treatment options.
Growth Factors:
- Increasing incidence of autoimmune diseases such as systemic lupus erythematosus (SLE) across the globe.
- Growing awareness about SLE and its treatment options among patients and healthcare professionals.
- Rising demand for immunosuppressants for the treatment of SLE patients, especially in developed countries.
- Technological advancements in the field of immunosuppressant drugs development that are helping to improve patient outcomes.
Scope Of The Report
Report Attributes
Report Details
Report Title
Immunosuppressant for Systemic Lupus Erythematosus Market Research Report
By Type
Cyclophosphamide, Mycophenolate Mofetil, Azathioprine, Cyclosporine A, Tacrolimus, Methotrexate, Leflunomide, Vincristine, Other
By Application
Hospital, Clinic, Pharmacy, Other
By Companies
Alcon, Alkem Laboratories, Allergan, Amneal Pharmaceuticals, Astellas Pharma, Baxter, Beijing Jialin Pharmaceutical, Genentech, Jubilant Cadista, LGM Pharma, LingNan Pharmaceutical, Merck, Mimetogen Pharmaceuticals, Mylan, Otsuka Pharmaceutical, Par Pharmaceutical, Pfizer, Powerdone, Regenerx Biopharmaceuticals, Roxane Laboratories, Sandoz, Sanofi, Santen Pharmaceutical, Takeda, Sine, Strides Pharma, Talon Therapeutics, Teva, United Biotech, West Ward Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Immunosuppressant for Systemic Lupus Erythematosus Market Report Segments:
The global Immunosuppressant for Systemic Lupus Erythematosus market is segmented on the basis of:
Types
Cyclophosphamide, Mycophenolate Mofetil, Azathioprine, Cyclosporine A, Tacrolimus, Methotrexate, Leflunomide, Vincristine, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alcon
- Alkem Laboratories
- Allergan
- Amneal Pharmaceuticals
- Astellas Pharma
- Baxter
- Beijing Jialin Pharmaceutical
- Genentech
- Jubilant Cadista
- LGM Pharma
- LingNan Pharmaceutical
- Merck
- Mimetogen Pharmaceuticals
- Mylan
- Otsuka Pharmaceutical
- Par Pharmaceutical
- Pfizer
- Powerdone
- Regenerx Biopharmaceuticals
- Roxane Laboratories
- Sandoz
- Sanofi
- Santen Pharmaceutical
- Takeda
- Sine
- Strides Pharma
- Talon Therapeutics
- Teva
- United Biotech
- West Ward Pharmaceuticals
Highlights of The Immunosuppressant for Systemic Lupus Erythematosus Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cyclophosphamide
- Mycophenolate Mofetil
- Azathioprine
- Cyclosporine A
- Tacrolimus
- Methotrexate
- Leflunomide
- Vincristine
- Other
- By Application:
- Hospital
- Clinic
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immunosuppressant for Systemic Lupus Erythematosus Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best immunosuppressant for systemic lupus erythematosus (SLE) will vary depending on the individual's specific symptoms and medical history. However, some common types of immunosuppressants used to treat SLE include: azathioprine (AZA), cyclophosphamide, corticosteroids, and mycophenolate mofetil.
Some of the major companies in the immunosuppressant for systemic lupus erythematosus market are Alcon, Alkem Laboratories, Allergan, Amneal Pharmaceuticals, Astellas Pharma, Baxter, Beijing Jialin Pharmaceutical, Genentech, Jubilant Cadista, LGM Pharma, LingNan Pharmaceutical, Merck, Mimetogen Pharmaceuticals, Mylan, Otsuka Pharmaceutical, Par Pharmaceutical, Pfizer, Powerdone, Regenerx Biopharmaceuticals, Roxane Laboratories, Sandoz, Sanofi, Santen Pharmaceutical, Takeda, Sine, Strides Pharma, Talon Therapeutics, Teva, United Biotech, West Ward Pharmaceuticals.
The immunosuppressant for systemic lupus erythematosus market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Immunosuppressant for Systemic Lupus Erythematosus Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Immunosuppressant for Systemic Lupus Erythematosus Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Immunosuppressant for Systemic Lupus Erythematosus Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Immunosuppressant for Systemic Lupus Erythematosus Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Immunosuppressant for Systemic Lupus Erythematosus Market Size & Forecast, 2018-2028
4.5.1 Immunosuppressant for Systemic Lupus Erythematosus Market Size and Y-o-Y Growth
4.5.2 Immunosuppressant for Systemic Lupus Erythematosus Market Absolute $ Opportunity
Chapter 5 Global Immunosuppressant for Systemic Lupus Erythematosus Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Type
5.2.1 Cyclophosphamide
5.2.2 Mycophenolate Mofetil
5.2.3 Azathioprine
5.2.4 Cyclosporine A
5.2.5 Tacrolimus
5.2.6 Methotrexate
5.2.7 Leflunomide
5.2.8 Vincristine
5.2.9 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Immunosuppressant for Systemic Lupus Erythematosus Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Pharmacy
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Immunosuppressant for Systemic Lupus Erythematosus Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Immunosuppressant for Systemic Lupus Erythematosus Analysis and Forecast
9.1 Introduction
9.2 North America Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Type
9.6.1 Cyclophosphamide
9.6.2 Mycophenolate Mofetil
9.6.3 Azathioprine
9.6.4 Cyclosporine A
9.6.5 Tacrolimus
9.6.6 Methotrexate
9.6.7 Leflunomide
9.6.8 Vincristine
9.6.9 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Pharmacy
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Immunosuppressant for Systemic Lupus Erythematosus Analysis and Forecast
10.1 Introduction
10.2 Europe Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Type
10.6.1 Cyclophosphamide
10.6.2 Mycophenolate Mofetil
10.6.3 Azathioprine
10.6.4 Cyclosporine A
10.6.5 Tacrolimus
10.6.6 Methotrexate
10.6.7 Leflunomide
10.6.8 Vincristine
10.6.9 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Pharmacy
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Immunosuppressant for Systemic Lupus Erythematosus Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Type
11.6.1 Cyclophosphamide
11.6.2 Mycophenolate Mofetil
11.6.3 Azathioprine
11.6.4 Cyclosporine A
11.6.5 Tacrolimus
11.6.6 Methotrexate
11.6.7 Leflunomide
11.6.8 Vincristine
11.6.9 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Pharmacy
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Immunosuppressant for Systemic Lupus Erythematosus Analysis and Forecast
12.1 Introduction
12.2 Latin America Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Type
12.6.1 Cyclophosphamide
12.6.2 Mycophenolate Mofetil
12.6.3 Azathioprine
12.6.4 Cyclosporine A
12.6.5 Tacrolimus
12.6.6 Methotrexate
12.6.7 Leflunomide
12.6.8 Vincristine
12.6.9 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Pharmacy
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Immunosuppressant for Systemic Lupus Erythematosus Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Type
13.6.1 Cyclophosphamide
13.6.2 Mycophenolate Mofetil
13.6.3 Azathioprine
13.6.4 Cyclosporine A
13.6.5 Tacrolimus
13.6.6 Methotrexate
13.6.7 Leflunomide
13.6.8 Vincristine
13.6.9 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Immunosuppressant for Systemic Lupus Erythematosus Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Pharmacy
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Immunosuppressant for Systemic Lupus Erythematosus Market: Competitive Dashboard
14.2 Global Immunosuppressant for Systemic Lupus Erythematosus Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alcon
14.3.2 Alkem Laboratories
14.3.3 Allergan
14.3.4 Amneal Pharmaceuticals
14.3.5 Astellas Pharma
14.3.6 Baxter
14.3.7 Beijing Jialin Pharmaceutical
14.3.8 Genentech
14.3.9 Jubilant Cadista
14.3.10 LGM Pharma
14.3.11 LingNan Pharmaceutical
14.3.12 Merck
14.3.13 Mimetogen Pharmaceuticals
14.3.14 Mylan
14.3.15 Otsuka Pharmaceutical
14.3.16 Par Pharmaceutical
14.3.17 Pfizer
14.3.18 Powerdone
14.3.19 Regenerx Biopharmaceuticals
14.3.20 Roxane Laboratories
14.3.21 Sandoz
14.3.22 Sanofi
14.3.23 Santen Pharmaceutical
14.3.24 Takeda
14.3.25 Sine
14.3.26 Strides Pharma
14.3.27 Talon Therapeutics
14.3.28 Teva
14.3.29 United Biotech
14.3.30 West Ward Pharmaceuticals
